Elicit Plant
Elicit Plant, a French agribiotechnology company formed in 2017, has developed a proprietary technology platform that increases the physiological resilience of crops while preserving natural resources. With laboratories in the Charente region of France, and a Brazilian branch in Sao Paulo, the firm has developed an innovative biostimulant using phytosterol, a molecule found in plants. The solution naturally boosts plants' metabolism, reducing the need for water and strengthening resistance to water stress. Elicit Plant's products are aimed at the €4 billion global market for biostimulants.
Sector
Industrial Biotech
Strategies
Industrial Biotech
Status
Live
Website
www.elicit-plant.com
Related News
Strategic partnership for sustainable agriculture: Bayer and Elicit Plant join forces in France for maize cultivation
Elicit Plant accelerates its international expansion in response to climate change and challenges in the agricultural sector
Elicit Plant announces its upcoming US biosolution launch with demonstrated 20% reduction of water consumption in broad acre crops
Elicit Plant announces the appointment of Slavica Djonovic, Ph.D, as Chief Scientific Officer (CSO)
Elicit Plant makes C&EN’s list of '10 Start-Ups to Watch'
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.